Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Market by Technology, Route of Administration, Application, and Region 2025-2033" has been added to ...

According to SNS Insider, the global Antisense and RNAi Therapeutics Market was valued at USD 4.15 billion in 2023 and is expected to reach USD 18.48 billion by 2032, registering a compound annual ...

AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the ...

DALLAS, TX and MARTINSRIED, GERMANY / ACCESSWIRE / March 20, 2024 / Celanese Corporation (NYSE:CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a ...

Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, ...

Scientists at St. Jude Children's Research Hospital have found that they can reverse the effects of HNRNPH2-related neurodevelopmental disorder using antisense oligonucleotides (ASOs) in preclinical ...

Assessing the distribution of a medication in the brain is critical for the treatment of a vast range of neurological disorders, especially conditions such as Parkinson's and Alzheimer's diseases. To ...

Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target ...

Antisense oligonucleotides have emerged as a promising approach for treating neurodegenerative disease. They can dial down toxic proteins or help restore functional ones, and have been approved for ...

Definition: Antisense therapy is a treatment strategy that uses short, synthetic, single-stranded nucleic acids – called antisense oligonucleotides (ASOs) – to bind to a complementary RNA sequence ...